Autopsy report · NCT02608125
A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma
Cause of deathFunding or business
“focus portfolio on immune-mediated diseases”
Life of this trial
- Registered 1 month before it started.
- Ran for about 4 years 8 months before it stopped.
- 45 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Principia Biopharma, a Sanofi Company
- Sponsor type
- Industry
- Conditions
- Solid Tumors; Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter
- Interventions
- PRN1371
- Participants
- 45
- Sites
- 12
- Countries
- Spain, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.